Technology evaluation: NeuroVax, Immune Response Corp

Current Opinion in Molecular Therapeutics

Volumn 7, Issue 6, 2005, Pages 598-603

  Darlington, Cynthia L ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

AG 284; AI 208; ANERGIX; ANTIINFLAMMATORY AGENT; BETA INTERFERON; DRUG VEHICLE; EPITOPE; FREUND ADJUVANT; GLATIRAMER; IR 208; NATALIZUMAB; NEUROVAX; NEW DRUG; PEPTIDE BV13S1; PEPTIDE BV5S2; PEPTIDE BV6S5; RECEPTOR PROTEIN; SODIUM CHLORIDE; T LYMPHOCYTE RECEPTOR; TIPLIMOTIDE; TOVAXIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VACCINE;

CLINICAL TRIAL; DOSE RESPONSE; DRUG FORMULATION; DRUG MECHANISM; DRUG METABOLISM; DRUG SYNTHESIS; FLU LIKE SYNDROME; HUMAN; IMMUNOGENICITY; INJECTION SITE REACTION; MULTIPLE SCLEROSIS; NONHUMAN; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; REVIEW; SIDE EFFECT; STRUCTURE ACTIVITY RELATION;

CLINICAL TRIALS; DRUG EVALUATION, PRECLINICAL; DRUG INDUSTRY; HUMANS; MULTIPLE SCLEROSIS; PATENTS; VACCINES, SUBUNIT;

EID: 28844495974     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (35)

1. 304165 AntiTNF-α agents in the treatment of inflammation. Sekut L, Connolly K EXPERT OPIN INVESTIG DRUGS 1998 7 11 1825-1839
2. 350403 Connetics and XOMA sell T-cell receptor technology to the Immune Response Corp. Connetics Corp PRESS RELEASE 1999 December 13
3. 389787 Immune Response initiates phase II MS vaccine trial. Immune Response Corp PRESS RELEASE 2000 November 14
4. 391006 Immunity to T cell receptor peptides in multiple sclerosis. III. Preferential immurrogenicity of complementarity-determining region 2 peptides from disease-associated T cell receptor BV genes. Bourdette DN, Chou YK, Whitham RH, Buckner J, Kwon HJ, Nepom GT, Buenafe A, Cooper SA, Allegretta M, Hashim GA, Offner H, Vandenbark AA J IMMUNOL 1998 161 2 1034-1044
5. 441570 NeuroVax achieves primary endpoint in MS trial. Immune Response Corp PRESS RELEASE 2002 February 27
6. 463345 Immune Response: Restructuring to focus on Remune. Immune Response Corp PRESS RELEASE 2002 September 09
7. 529573 Canadian trial to assess Remune as drug-sparing therapy in HIV. Immune Response Corp PRESS RELEASE 2004 March 30
8. 530939 Immune Response to conduct NeuroVax phase II under new grant. Immune Response Corp PRESS RELEASE 2004 April 06
9. 535563 IRC's NeuroVax shows strong response in phase I/II MS study. The Immune Response Corp PRESS RELEASE 2004 April 29
10. 547266 IRC's NeuroVax is immunogenic in phase II MS trial. The Immune Response Corp PRESS RELEASE 2004 July 01
11. 575120 The IRC ramps up NeuroVax MS program. The Immune Response Corp PRESS RELEASE 2004 December 08
12. 580844 TCR peptide therapy in human autoimmune diseases. Vandenbark AA, Morgan E, Bartholomew R, Bourdette D, Whitham R, Carlo D, Gold D, Hashim G, Offner H NEUROCHEM RES 2001 26 6 713-730
13. 587626 Immune Response starts phase II MS trial of NeuroVax. The Immune Response Corp PRESS RELEASE 2005 March 01
14. 607359 Immune Response finds marker for MS Immune dysfunction. The Immune Response Corp PRESS RELEASE 2005 June 14
15. 607463 Decreased FOXP3 levels in multiple sclerosis patients. Huan J, Culbertson N, Spencer L, Bartholomew R, Burrows GG, Chou YK, Bourdette D, Ziegler SF, Offner H, Vandenbark AA J NEUROSCI RES 2005 81 1 45-52
16. 608182 The potential role for statins in the treatment of multiple sclerosis. Darlington CL CURR OPIN INVESTIG DRUGS 2005 6 7 667-671
17. 608606 The Immune Response Corporation's NeuroVax demonstrates increase in FOXP3 gene marker levels and Treg cell functional activity in MS patients to levels similar to human controls. The Immune Response Corp PRESS RELEASE 2005 June 21
18. 623079 Regulatory T-cell lineage specification by the forkhead transcription factor FOXP3. Fontenot JD, Rasmussen JP, Williams LM, Dooley JL, Farr AG, Rudensky AY IMMUNITY 2005 22 2 329-341
19. 623082 Both rat and mouse T-cell receptors specific for the encephalitogenic determinant of myelin basic protein use similar vα and vβ chain genes even though the major histocompatibility complex and encephalitogenic determinants being recognized are different. Burns FR, LI XB, Shen N, Offner H, Chou YK, Vandenbark AA, Heber-Katz E J EXP MED 1989 169 1 27-33
20. 623085 Antibodies specific for VB8 receptor peptide suppress experimental autoimmune encephalomyelitis. Hashim GA, Vandenbark AA, Galang AB, Kiamanduros T, Carvalho E, Srinivasan J, Jones R, Vainiene M, Morrison WJ, Offner H J IMMUNOL 1990 144 12 4621-4627
21. 624193 Pathogenesis of multiple sclerosis. Prat A, Antel J CURR OPIN NEUROL 2005 18 3 225-230
22. 624224 Immunity to TCR peptides, in multiple sclerosis. II, T cell recognition of vβ 5.2 and vβ 6.1 CDR2 peptides. Chou YK, Morrison WJ, Weinberg AD, Dedrick R, Whitham R, Bourdette DN, Hashim G, Offner H, Vandenbark AA J IMMUNOL 1994 152 5 2520-2529
23. 624460 Chemokine receptor expression on T cells in blood and cerebrospinal fluid at relapse and remission of multiple sclerosis: Imbalance of Th1/Th2-associated chemokine signaling. Misu T, Onodera H, Fujihara K, Matsushima K, Yoshie O, Okita N, Takase S, Itoyama Y J NEUROIMMUNOL 2001 114 1-2 207-212
24. 624463 Transcriptional analysis of multiple sclerosis brain lesions reveals a complex pattern of cytokine expression. Baranzini SE, Elfstrom C, Chang SY, Butunoi C, Murray R, Higuchi R, Oksenberg JR J IMMUNOL 2000 165 11 6576-6582
25. 624472 T cell receptor peptides in treatment of autoimmune disease: Rationale and potential. Vandenbark AA, Hashim GA, Offner H J NEUROSCI RES 1996 43 4 391-402
26. 624659 Immunization with a synthetic T-cell receptor V-region peptide protects against experimental autoimmune encephalomyelitis. Vandenbark AA, Hashim G, Offner H NATURE 1989 341 6242 541-544
27. 624660 Preferential T-cell receptor β-chain variable gene use in myelin basic protein-reactive T-cell clones from patients with multiple sclerosis. Kotzin BL, Karuturi S, Chou YK, Lafferty J, Forrester JM, Better M, Nedwin GE, Offner H, Vandenbark AA PROC NATL ACAD SCI USA 1991 88 20 9161-9165
28. 624686 Mechanisms of immunomodulation by glatiramer acetate. Gran B, Tranquill LR, Chen M, Bielekova B, Zhou W, Dhib-Jalbut S, Martin R NEUROLOGY 2000 55 11 1704-1714
29. 624687 Demyelination and inhibition of tumor necrosis factor (TNF). Magnano MD, Robinson WH, Genovese MC CLIN EXP RHEUMATOL 2004 22 5 Suppl 35 S134-S140
30. 625198 Biogen Idec and Elan submit Supplemental Biologics License Application to the FDA for TYSABRI(R) in multiple sclerosis. Biogen Idec Inc PRESS RELEASE 2005 September 26
31. 626023 Challenges and opportunities: What we are learning from the clinical natalizumab experience. Kachuck NJ EXPERT REV NEUROTHER 2005 5 5 605-615
32. 629419 A highly immunogenic trivalent T cell receptor peptide vaccine for multiple sclerosis. Bourdette DN, Edmonds E, Smith C, Bowen JD, Guttmann CR, Nagy ZP, Simon J, Whitham R, Lovera J, Yadav V, Mass M et al MULT SCLER 2005 11 5 552-561
33. 630882 Regulatory T cells: Development, function and role in autoimmunity. Lan RY, Ansari AA, Lian ZX, Gershwin ME AUTOIMMUN REV 2005 4 6 351-363
34. 631036 Elan reports third quarter 2005 financial results. Elan Corp plc; PRESS RELEASE 2005 October 27
35. 632570 NeuroVax clinical trial information. Bartholomew R COMPANY COMMUNICATION 2005 November 03